|4/AJun 28, 8:47 AM ET

Palmetto Partners, Ltd. 4/A

4/A · XERIS PHARMACEUTICALS INC · Filed Jun 28, 2018

Insider Transaction Report

Form 4/AAmended
Period: 2018-06-25
Transactions
  • Conversion

    Series C Preferred Stock

    2018-06-25797,3840 total
    Common Stock (447,686 underlying)
  • Conversion

    Series B Preferred Stock

    2018-06-251,657,1250 total
    Common Stock (930,383 underlying)
  • Conversion

    Series C Preferred Stock

    2018-06-251,036,5990 total
    Common Stock (581,992 underlying)
Footnotes (5)
  • [F1]The securities are owned by Palmetto Partners 2014, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2015, LP.
  • [F2]Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis, at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
  • [F3]The securities are owned by Palmetto Partners 2015, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2014, LP.
  • [F4]The securities are owned by Palmetto Partners, Ltd., who is a member of a group with Palmetto Partners 2014, LP and Palmetto Partners 2015, LP.
  • [F5]This Form 4/A is being filed to correct the title of the derivative securities held by the Reporting Persons.

Documents

1 file
  • 4
    edgar.xml

    PRIMARY DOCUMENT